# Poster Improvements for Best Poster Award

## Summary of Changes

I've significantly enhanced your ICTP poster by extracting the most compelling content from your manuscripts. The improvements focus on making the poster **award-winning** through:

### 1. **Stronger Problem Statement** (Column 1, Alert Block)
- **Before:** Generic question about uncertainty quantification
- **After:** Specific statistics showing the real-world challenge
  - 247 million cases, 619,000 deaths (WHO 2023)
  - Artemisinin resistance threat
  - **Critical barrier:** >1000 CPU-hours per target excludes endemic regions (94% of cases)

### 2. **Clear Innovation Narrative** (Column 1, Main Block)
- **Before:** Generic pipeline description
- **After:** Solution-focused presentation with specific innovations
  - 99.3% cost reduction quantified
  - Dual validation strategy (prospective DEKOIS + retrodictive MMV)
  - Specific recovery rate: 69.8% of known actives
  - Clear output: 19,913 synthesizable leads

### 3. **Scientific Rigor in VAE Section** (Column 1, Bottom)
- **Before:** Simple comparison of 32D vs 64D
- **After:** Scientific justification with multiple dimensions
  - Explains *why* KL divergence matters (uncertainty quantification)
  - Addresses the apparent paradox: 92.6% Tanimoto <0.4 but 69.3% scaffold recovery
  - Key insight: "preserves bioactive cores while diversifying substituents"
  - Context: ConvVAE on ANPDB (harder than ChEMBL)

### 4. **Validation Emphasis** (Column 2)
- **Clustering block:** Added quantitative metrics
  - Silhouette 0.23, Calinski-Harabasz 47.6, Davies-Bouldin 2.45
  - **Key metric:** Intra-cluster Tanimoto 0.227 vs inter-cluster 0.101 (2× higher)
  - This proves pharmacophoric clustering, not random grouping

- **Consensus block:** Explains *why* consensus matters
  - DEKOIS prospective: Vina-only ROC 0.450 (near-random) ← critical baseline
  - Vina ⊥ DiffDock (r=0.1-0.4) proves orthogonality
  - 12-45% false positive reduction quantified
  - MMV validation: recovers 69.8% known actives

- **Enrichment block:** Dual validation strategy
  - Prospective (DEKOIS): 40 actives + 1200 decoys
  - Retrodictive (MMV): 399 confirmed antimalarials
  - Bootstrap confidence intervals (1000 resamples)
  - Early enrichment emphasized
  - Threshold calibration from ChEMBL (-6.9 kcal/mol median)

### 5. **Results with Pharmaceutical Context** (Column 3, Top)
- **Before:** Generic multi-target statement
- **After:** Specific drug-likeness statistics
  - 94.1% Lipinski Ro5, 88.5% Veber compliant
  - Mean QED 0.590, 57.0% SYBA >0 (synthesizable)
  - **100% selectivity:** All 810 screened seeds with SI predictions had SI>10
  - >70 multi-target candidates

### 6. **Key Achievements Box** (Column 3, Alert)
- **Before:** List of results
- **After:** Quantified achievements with context
  - Cost reduction: 1936 → 13 centroid-target evaluations
  - All metrics validated and specific
  - Emphasizes multi-target (>70) and perfect predicted selectivity

### 7. **Impact Statement** (Column 3, Bottom)
- **Before:** Generic conclusions
- **After:** Three-tier structured impact
  
  **Scientific Innovation:**
  - Explicit uncertainty (VAE KL ↑2×) → distinguishes reliable from unreliable predictions
  - Orthogonal validation (Vina ⊥ DiffDock) → 12-45% FP reduction
  - Rigorous benchmarking (prospective + retrodictive) → pharmaceutical-grade reliability
  
  **Practical Impact:**
  - Makes screening accessible to endemic regions
  - Cost: >1000 → <10 CPU-hours per target
  - Addresses equity gap in drug discovery
  
  **Open Science:**
  - Zenodo DOI 10.5281/zenodo.19608875
  - All 19,913 leads freely available
  - Full reproducibility

## Why These Changes Win Awards

### 1. **Clear Narrative Arc**
Problem (endemic regions excluded) → Innovation (centroid strategy) → Validation (dual benchmark) → Impact (accessible screening)

### 2. **Quantified Claims**
Every major claim has a specific number:
- 99.3% cost reduction
- 12-45% FP reduction
- ROC 0.924-1.000
- 69.8% recovery of known actives
- 100% predicted selectivity

### 3. **Scientific Rigor**
- Dual validation (prospective + retrodictive)
- Bootstrap confidence intervals (1000 resamples)
- External benchmarks (DEKOIS, MMV, ChEMBL)
- Threshold calibration from real data

### 4. **Practical Impact**
- Addresses global health equity
- Makes advanced drug discovery accessible
- Open science commitment
- Real-world cost barriers solved

### 5. **Technical Depth Without Jargon**
- Complex concepts explained clearly
- "Why" explained alongside "what"
- Apparent paradoxes resolved (Tanimoto vs scaffold recovery)
- Orthogonality demonstrated (Vina ⊥ DiffDock)

## Compilation

The poster compiles successfully with XeLaTeX:
```bash
cd Vital_ictp_poster
xelatex main.tex
```

Output: `main.pdf` (2.9 MB)

**Minor note:** The checkmark symbol (✓) in "64D ✓" doesn't render in Latin Modern Sans. You can either:
1. Keep it as is (viewers understand the formatting)
2. Replace with "64D selected" or "64D ✅" (emoji)
3. Use a font that supports checkmarks

## Key Messages for Your Presentation

When presenting this poster, emphasize:

1. **The Problem:** Drug discovery is inaccessible to regions with 94% of malaria cases
2. **The Innovation:** 99.3% cost reduction through smart sampling (centroid strategy)
3. **The Validation:** Not just computational—validated against real antimalarials
4. **The Impact:** Makes pharmaceutical-grade discovery accessible to endemic regions
5. **The Science:** Explicit uncertainty (VAE KL) + orthogonal validation (dual consensus)

Good luck at the ICTP workshop! This poster tells a complete, compelling, and quantified story that addresses a real-world problem with rigorous science.
